Boston Scientific Guides FY Adjusted EPS to $3.16-$3.18
BSX is trading near its 52-week low of $41.385 (9.7% above the low).
Summary
Boston Scientific issued full-year adjusted EPS guidance of $3.16 to $3.18. The range lands after a rough stretch: the August 25 cyberattack forced the company to warn on September 8 that it would miss prior Q3 and full-year sales and adjusted EPS guidance, so this is the first look at where management now sees the year landing. The spread is narrow, implying limited room for further operational surprises, but the key question is how far below the original plan this reset sits. Third-quarter results showed EPS of 40c, sales of $5.14B and adjusted EPS of 73c, with organic sales up 1.5%. For 2026 the company now sees sales up about 4.25% and organic sales up about 3.75%, while it sees fourth-quarter sales down 1%-3%.
At the time of this announcement, BSX was trading at $45.39 on NYSE in the Life Sciences sector, with a market capitalization of approximately $65.3B. The 52-week trading range was $41.39 to $105.65. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.